Open AccessMOLECULAR GENETIC TESTING IN DIAGNOSTICS OF LUNG CANCER AND OVARIAN CARCINOMA WITH THE USAGE OF CYTOLOGICAL SPECIMENS
Author(s) -
О. Г. Григорук,
E. I Pupkova,
Л. М. Базулина,
А. Ф. Лазарев
Publication year - 2017
Publication title -
rossijskij onkologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2412-9119
pISSN - 1028-9984
DOI - 10.18821/1028-9984-2017-22-4-214-218
Subject(s) - kras , serous fluid , ovarian carcinoma , ovarian cancer , serous carcinoma , gene mutation , adenocarcinoma , cancer research , lung cancer , carcinoma , gene , mutation , pathology , oncology , medicine , cancer , biology , genetics
This article presents results of the introduction in practical oncology of molecular genetic investigations performed with the use of tumor DNA cells taken from the cytological specimens. There was investigated the molecular genetic characteristics of cytological specimens from 126 patients. In 80 cases with the proved diagnosis of pulmonary adenocarcinoma (n = 80) EGFR gene mutations were noted in 11.7% cases. KRAS, BRAF and BRCA1/2 gene mutations were determined in 46 women suffering from serous ovarian carcinoma. KRAS gene mutations in cells of ovarian low-grade serous carcinoma were determined in 62.5% of patients, BRAF- in 12.5% cases. BRCA1 gene mutations have been determined in 14.3% cases from the ovarian high-grade serous carcinoma group. In conditions of the presence of the sufficient amount of tumor cells the cytological material is the fully-featured material for molecular genetic investigations. The investigation both of EGFR gene mutations in pulmonary adenocarcinoma cases and KRAS, BRAF, BRCA1/2 gene mutations with serous ovarian carcinoma are mandatory in the appointment of targeted therapy.